Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Brief Summary: The purpose of this phase 3B trial was to see how well a new trial drug (degarelix) works in terms of reducing the size of the prostate volume in prostate cancer patients who were scheduled to undergo subsequent radiotherapy for treatment of their prostate cancer. Prior to receiving radiotherapy, it is recommended that patients with intermediate to high risk prostate cancer are pre-treated with hormone therapy (so-called neoadjuvant therapy) which is known to reduce the size of the prostate and thereby decrease the required radiation field and enable a more safe and effective treatment. In this trial, participants were randomly selected (like flipping a coin) to receive either degarelix given alone or a standard hormone therapy (combination of goserelin and bicalutamide. The treatment was given for three months and the prostate size was measured by ultra sound at the beginning and at the end of the trial. The participants were required to come to the clinic for 5 or 6 visits during the three months.


Options:
A: Arm Label: Degarelix 240 mg / 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Degarelix 240 mg / 80 mg | Intervention Type: DRUG; Name: Degarelix 240 mg / 80 mg; Assigned to Arm(s): Degarelix 240 mg / 80 mg
B: Arm Label: Degarelix 240 mg/80 mg; Type: EXPERIMENTAL; Interventions: Drug: Degarelix | Arm Label: Goserelin (3.6 mg) + bicalutamide (50 mg); Type: ACTIVE_COMPARATOR; Interventions: Drug: Goserelin, Drug: Bicalutamide | Intervention Type: DRUG; Name: Degarelix; Assigned to Arm(s): Degarelix 240 mg/80 mg | Intervention Type: DRUG; Name: Goserelin; Assigned to Arm(s): Goserelin (3.6 mg) + bicalutamide (50 mg) | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): Goserelin (3.6 mg) + bicalutamide (50 mg)
C: Arm Label: Degarelix; Type: EXPERIMENTAL; Interventions: Drug: Degarelix | Arm Label: Degarelix + Casodex; Type: EXPERIMENTAL; Interventions: Drug: Degarelix, Drug: Casodex | Arm Label: LHRH Agonist + Casodex; Type: ACTIVE_COMPARATOR; Interventions: Drug: Casodex, Drug: LHRH Agonist | Intervention Type: DRUG; Name: Degarelix; Assigned to Arm(s): Degarelix, Degarelix + Casodex | Intervention Type: DRUG; Name: Casodex; Assigned to Arm(s): Degarelix + Casodex, LHRH Agonist + Casodex | Intervention Type: DRUG; Name: LHRH Agonist; Assigned to Arm(s): LHRH Agonist + Casodex
D: Arm Label: Degarelix 240 mg/80 mg; Type: EXPERIMENTAL; Interventions: Drug: Degarelix | Arm Label: Goserelin (3.6 mg) + bicalutamide (50 mg); Type: ACTIVE_COMPARATOR; Interventions: Drug: Goserelin, Drug: Bicalutamide | Intervention Type: DRUG; Name: Degarelix; Assigned to Arm(s): Degarelix 240 mg/80 mg | Intervention Type: DRUG; Name: Goserelin; Assigned to Arm(s): Goserelin (3.6 mg) + bicalutamide (50 mg) | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): Goserelin (3.6 mg) + bicalutamide (50 mg)

Answer: D